Where is dana farber

At Dana-Farber, you not only get a cancer specialist, but you also get a specialist in your particular type of cancer. From an individualized treatment plan that recognizes who you are, to specialized therapies based on the genetic profile of your specific cancer — everything we do is centered around your unique needs.

Patients of every age need care tailored to their needs. Just as caring for children requires a distinct set of approaches and techniques, the same is true for adults across the age span. For children, for young adults, for older adults — at Dana-Farber, our experts have the clinical expertise, experience, and compassion to treat you, your child, or your loved one with the specialized approach they need.

We care for adults and children with cancer in our specialized treatment centers, focused on specific cancer types. Our teams of specialists work closely together to offer patients the latest therapies and clinical services, including access to innovative clinical trials. We understand that cancer affects patients and their families in many ways. We offer a wide range of services, from financial planning to creative arts to spiritual care and more, to support our patients through their cancer experiences.

Patients and their loved ones often face many new concerns and anxieties following a cancer diagnosis. Nutrition experts at Dana-Farber will help you follow a healthy diet during and after your cancer treatment. We have special training in oncology and nutrition, and base our advice on scientifically sound nutrition research.

The Leonard P. Zakim Center for Integrative Therapies and Healthy Living at Dana-Farber is dedicated to enhancing the quality of life for cancer patients and their families by incorporating complementary therapies — including acupuncture, massage, Reiki, meditation, creative arts, and movement classes — into traditional cancer care.

Our clinicians — medical oncologists, surgeons, radiation oncologists, radiologists, pathologists, and nursing staff — have deep experience treating your particular type of cancer. Our team approach to cancer care ensures that you will receive the combination of treatments that is best for you.

Dana-Farber Cancer Institute remains true to Dr. Sidney Farber's vision of a cancer center that is as dedicated to discoveries in cancer research as it is to delivering compassionate, patient-centered care. Dana-Farber physicians and researchers have helped develop many of the very latest therapies — from harnessing the immune system to targeted therapies based on the genetics of your cancer.

Which means we can provide the latest and best care, sooner. Your gift to Dana-Farber supports our lifesaving mission. Every gift helps to advance our progress in the fight against cancer. Appointments Adult : General information: Weymouth, MA. The medical oncology physician suite at 51 Performance Drive has closed. Read disclaimer about translations Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated.

Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions.

You may request a live medical interpreter for a discussion about your care. Tolaney, MD, MPH, discusses progress made with escalation and de-escalation strategies in HER2-positive breast cancer, ongoing research with immunotherapy, and efforts being made to further move the needle forward.

Toni K. Adjuvant treatment with pembrolizumab led to a significant improvement in disease-free survival compared with placebo after nephrectomy in patients with renal cell carcinoma who are at high risk for recurrence, as underscored by data from the pivotal phase 3 KEYNOTE trial. Jorge J. When George P. Canellos, MD, first joined the field of oncology in the s, many of his peers thought he was making huge mistake. Increased intake of vitamin D was associated with a decreased risk of early-onset colorectal cancer and precursors in younger women between the ages of 25 years and 42 years.